Omeros (NASDAQ:OMER) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research report report published on Wednesday.

OMER has been the subject of a number of other research reports. Cantor Fitzgerald restated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research report on Thursday, November 14th. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Finally, Rodman & Renshaw initiated coverage on shares of Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average target price of $9.00.

Omeros Price Performance

Shares of Omeros stock opened at $6.03 on Wednesday. Omeros has a 12-month low of $1.60 and a 12-month high of $7.51. The company’s fifty day simple moving average is $4.24 and its two-hundred day simple moving average is $4.14.

Hedge Funds Weigh In On Omeros

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets raised its stake in shares of Omeros by 75.5% in the first quarter. BNP Paribas Financial Markets now owns 30,102 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 12,951 shares during the last quarter. Comerica Bank lifted its stake in Omeros by 20.0% during the 1st quarter. Comerica Bank now owns 30,000 shares of the biopharmaceutical company’s stock valued at $104,000 after acquiring an additional 5,000 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Omeros by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock valued at $11,213,000 after acquiring an additional 81,348 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Omeros by 16.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares during the last quarter. Finally, AQR Capital Management LLC bought a new stake in shares of Omeros in the second quarter worth approximately $105,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.